{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:07:40Z","timestamp":1789247260267,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017608","name":"Shenzhen International Cooperation Research Project","doi-asserted-by":"publisher","award":["GJHZ20240218114459012"],"award-info":[{"award-number":["GJHZ20240218114459012"]}],"id":[{"id":"10.13039\/501100017608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jceh.2026.103637","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:22:34Z","timestamp":1787181754000},"page":"103637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diabetes-associated Alterations in the Gut Microbiota\u2013metabolite Profile of NAFLD Under Complex Clinical Conditions"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6168-6515","authenticated-orcid":false,"given":"Jieying","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2026.103637_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103637_bib6","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.28697","article-title":"Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients","volume":"65","author":"Leung","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103637_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/postgradmedj-2018-136316","article-title":"Diagnosis and management of non-alcoholic fatty liver disease","volume":"95","author":"Jennison","year":"2019","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jceh.2026.103637_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cmet.2019.08.002","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"30","author":"Loomba","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jceh.2026.103637_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-021-00499-1","article-title":"The promise of the gut microbiome as part of individualized treatment strategies","volume":"19","author":"Schupack","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tcm.2018.08.003","article-title":"Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases","volume":"29","author":"Schiattarella","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jceh.2026.103637_bib12","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2026.103637_bib13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hep.29179","article-title":"Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis","volume":"67","author":"Herrmann","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103637_bib14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2026.103637_bib15","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1210\/clinem\/dgae499","article-title":"Exploring the gut microbiota: key insights into its role in obesity, metabolic syndrome, and type 2 diabetes","volume":"109","author":"Sasidharan Pillai","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jceh.2026.103637_bib16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103637_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102503","article-title":"Gut microbiota and genetic polymorphisms appear to drive disease expression of nonalcoholic fatty liver disease in lean individuals","volume":"15","author":"Anirvan","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41588-019-0350-x","article-title":"Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases","volume":"51","author":"Sanna","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.jceh.2026.103637_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/ajcn\/nqac085","article-title":"The effects of SCFAs on glycemic control in humans: a systematic review and meta-analysis","volume":"116","author":"Cherta-Murillo","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jceh.2026.103637_bib20","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00592-022-01948-2","article-title":"Gut microbial products valerate and caproate predict renal outcome among the patients with biopsy-confirmed diabetic nephropathy","volume":"59","author":"Zhong","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jceh.2026.103637_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.943427","article-title":"Gut microbiota composition in prediabetes and newly diagnosed type 2 diabetes: a systematic review of observational studies","volume":"12","author":"Letchumanan","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jceh.2026.103637_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2023.104601","article-title":"Gut microbiota dysbiosis -associated obesity and its involvement in cardiovascular diseases and type 2 diabetes. A systematic review","volume":"151","author":"Hamjane","year":"2024","journal-title":"Microvasc Res"},{"key":"10.1016\/j.jceh.2026.103637_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3350\/cmh.2020.0129","article-title":"The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease","volume":"27","author":"Jennison","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103637_bib25","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2026.103637_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1018093","article-title":"A systematic review and meta-analysis of gut microbiota in diabetic kidney disease: comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals","volume":"13","author":"Han","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jceh.2026.103637_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jceh.2026.103637_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1277102","article-title":"The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective","volume":"14","author":"Fu","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:20:13Z","timestamp":1789244413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688326001696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0973688326001696"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103637","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes-associated Alterations in the Gut Microbiota\u2013metabolite Profile of NAFLD Under Complex Clinical Conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian National Association for Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103637"}}